(Q38854076)

7 September 2017

Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies (English)

1 reference

7 September 2017

John B Dever

1

1 reference

7 September 2017

Julie H Ducom

2

1 reference

7 September 2017

Ariel Ma

3

1 reference

7 September 2017

Joseph Nguyen

4

1 reference

7 September 2017

Lin Liu

5

1 reference

7 September 2017

Ann Herrin

6

1 reference

7 September 2017

Erik J Groessl

7

1 reference

7 September 2017

Samuel B Ho

8

1 reference

7 September 2017

4 April 2017

1 reference

Digestive Diseases and Sciences

7 September 2017

1 reference

7 September 2017

62

1 reference

7 September 2017

6

1 reference

7 September 2017

1472-1479

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-017-4548-4

7 September 2017

0 references

cites work

Toward a more accurate estimate of the prevalence of hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Gaps in the achievement of effectiveness of HCV treatment in national VA practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Management of chronic hepatitis C in veterans: the potential of integrated care models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Integrating hepatitis prevention services into a substance use disorder clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4548-4

An assessment of concurrent drug and alcohol use among patients seeking treatment for hepatitis C.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28378246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28378246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10620-017-4548-4

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference